We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Amazon, Tesla, UnitedHealth Group, T-Mobile and Moderna
Read MoreHide Full Article
For Immediate Release
Chicago, IL – June 9, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Amazon.com, Inc. (AMZN - Free Report) , Tesla, Inc. (TSLA - Free Report) , UnitedHealth Group Incorporated (UNH - Free Report) , T-Mobile US, Inc. (TMUS - Free Report) and Moderna, Inc. (MRNA - Free Report) .
Here are highlights from Tuesday’s Analyst Blog:
Top Research Reports for Amazon, Tesla and UnitedHealth
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Tesla, and UnitedHealth Group. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Shares of Amazon have underperformed the broader market in the last one-year period (+23% vs. +36.2%) on a combination of worries, ranging from the company's less advantageous standing in the post-pandemic world to negative sentiment on all 'growthy' stocks in a rising interest rate environment.
That said, the Zacks analyst believes that Amazon is gaining on solid Prime momentum owing to its ultrafast delivery services and strong content portfolio. Further, solid growth in its online stores sales remains a positive.
Additionally, the strong adoption rate of AWS is aiding the company's cloud dominance. Moreover, expanding AWS services portfolio is continuously helping Amazon in gaining further momentum among the customers. However, accelerating coronavirus related expenses remain risks for the company's margin expansion in the near term.
Tesla shares have gained +0.1% over the last six months against the Zacks Domestic Automotive industry's gain of +2.6%. The Zacks analyst believes that the company has a first-mover advantage in the e-mobility space, with high range vehicles and superior technology.
Further, robust Model 3/Y demand, Shanghai Gigafactory prospects, an amazing line-up of upcoming products and aggressive expansion efforts bode well for the firm. However, an unclear 2021 vehicle delivery target raises a concern. Also, waning margins for Model S/X, chip crunch and lofty valuation of the firm are other concerns.
Shares of UnitedHealth have gained +14.1% in the past three months against the Zacks Medical Insurance industry's gain of +13.1%. The Zacks analyst believes that the company's top line has been boosted by new deals, renewed agreements and expansion of service offerings.
UnitedHealth remains well poised to gain from its government business. Further, a sturdy balance sheet and consistent cash flow generation have led to a solid capital position, thereby enabling the company to engage in share buybacks and dividend payments. However, it is witnessing a slowdown in international and commercial business.
Other noteworthy reports we are featuring today include T-Mobile US and Moderna.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 77 billion devices by 2025, creating a $1.3 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 4 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2022.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Amazon, Tesla, UnitedHealth Group, T-Mobile and Moderna
For Immediate Release
Chicago, IL – June 9, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Amazon.com, Inc. (AMZN - Free Report) , Tesla, Inc. (TSLA - Free Report) , UnitedHealth Group Incorporated (UNH - Free Report) , T-Mobile US, Inc. (TMUS - Free Report) and Moderna, Inc. (MRNA - Free Report) .
Here are highlights from Tuesday’s Analyst Blog:
Top Research Reports for Amazon, Tesla and UnitedHealth
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Tesla, and UnitedHealth Group. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Shares of Amazon have underperformed the broader market in the last one-year period (+23% vs. +36.2%) on a combination of worries, ranging from the company's less advantageous standing in the post-pandemic world to negative sentiment on all 'growthy' stocks in a rising interest rate environment.
That said, the Zacks analyst believes that Amazon is gaining on solid Prime momentum owing to its ultrafast delivery services and strong content portfolio. Further, solid growth in its online stores sales remains a positive.
Additionally, the strong adoption rate of AWS is aiding the company's cloud dominance. Moreover, expanding AWS services portfolio is continuously helping Amazon in gaining further momentum among the customers. However, accelerating coronavirus related expenses remain risks for the company's margin expansion in the near term.
(You can read the full research report on Amazon here >>>)
Tesla shares have gained +0.1% over the last six months against the Zacks Domestic Automotive industry's gain of +2.6%. The Zacks analyst believes that the company has a first-mover advantage in the e-mobility space, with high range vehicles and superior technology.
Further, robust Model 3/Y demand, Shanghai Gigafactory prospects, an amazing line-up of upcoming products and aggressive expansion efforts bode well for the firm. However, an unclear 2021 vehicle delivery target raises a concern. Also, waning margins for Model S/X, chip crunch and lofty valuation of the firm are other concerns.
(You can read the full research report on Tesla here >>>)
Shares of UnitedHealth have gained +14.1% in the past three months against the Zacks Medical Insurance industry's gain of +13.1%. The Zacks analyst believes that the company's top line has been boosted by new deals, renewed agreements and expansion of service offerings.
UnitedHealth remains well poised to gain from its government business. Further, a sturdy balance sheet and consistent cash flow generation have led to a solid capital position, thereby enabling the company to engage in share buybacks and dividend payments. However, it is witnessing a slowdown in international and commercial business.
(You can read the full research report on UnitedHealth here >>>)
Other noteworthy reports we are featuring today include T-Mobile US and Moderna.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 77 billion devices by 2025, creating a $1.3 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 4 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2022.
Click here for the 4 trades >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.